journal cover

Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors

Cancer Immunology Research

Dec 7, 2019

Florence SchrammeBenoît J Van den Eynde

Abstract

Tryptophan 2,3-dioxygenase (TDO) is an enzyme that degrades tryptophan into kynurenine and thereby induces immunosuppression. Like indoleamine 2,3-dioxygenase (IDO1), TDO is considered as a relevant drug target to improve the efficacy of cancer immunotherapy. However, its role in variou...read more

Mentioned in this Paper

Tryptophan
Diet
Tumor Tissue Sample
Kynurenine
Inhibitors
Neoplasms
Hepatic
TDO2
Indoleamine-Pyrrole 2,3,-Dioxygenase
Tryptophan 2,3 Dioxygenase Activity
3
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

The Nuffield Department of Medicine

Find the latest research from the Nuffield Department of Medicine at the University of Oxford here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

Proceedings of the National Academy of Sciences of the United States of AmericaFebruary 7, 2012
Luc PilotteBenoît J Van den Eynde
Bulletin et mémoires de l'Académie royale de médecine de Belgique

A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase

Bulletin et mémoires de l'Académie royale de médecine de BelgiqueMay 11, 2004
B Van den Eynde
© 2020 Meta ULC. All rights reserved

Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors

Cancer Immunology Research

Dec 7, 2019

Florence SchrammeBenoît J Van den Eynde

PMID: 31806638

DOI: 10.1158/2326-6066.cir-19-0041

Abstract

Tryptophan 2,3-dioxygenase (TDO) is an enzyme that degrades tryptophan into kynurenine and thereby induces immunosuppression. Like indoleamine 2,3-dioxygenase (IDO1), TDO is considered as a relevant drug target to improve the efficacy of cancer immunotherapy. However, its role in variou...read more

Mentioned in this Paper

Tryptophan
Diet
Tumor Tissue Sample
Kynurenine
Inhibitors
Neoplasms
Hepatic
TDO2
Indoleamine-Pyrrole 2,3,-Dioxygenase
Tryptophan 2,3 Dioxygenase Activity
3

Similar Papers Found In These Feeds

The Nuffield Department of Medicine

Find the latest research from the Nuffield Department of Medicine at the University of Oxford here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

Proceedings of the National Academy of Sciences of the United States of AmericaFebruary 7, 2012
Luc PilotteBenoît J Van den Eynde
Bulletin et mémoires de l'Académie royale de médecine de Belgique

A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase

Bulletin et mémoires de l'Académie royale de médecine de BelgiqueMay 11, 2004
B Van den Eynde
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.
/papers/inhibition-of-tryptophan-dioxygenase-activity/31806638